Last reviewed · How we verify
DPT-IPV
DPT-IPV is a combination vaccine that provides immunization against diphtheria, pertussis, tetanus, and inactivated poliovirus.
DPT-IPV is a combination vaccine that provides immunization against diphtheria, pertussis, tetanus, and inactivated poliovirus. Used for Primary immunization against diphtheria, pertussis, tetanus, and poliomyelitis in infants and children, Booster immunization in pediatric populations.
At a glance
| Generic name | DPT-IPV |
|---|---|
| Also known as | Tetrabik |
| Sponsor | Tanabe Pharma Corporation |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This is a multi-component vaccine that stimulates the immune system to produce antibodies against four distinct pathogens: Corynebacterium diphtheriae (diphtheria), Bordetella pertussis (pertussis/whooping cough), Clostridium tetani (tetanus), and poliovirus types 1, 2, and 3. The vaccine contains inactivated or toxoid forms of these antigens, allowing safe immunization without causing disease.
Approved indications
- Primary immunization against diphtheria, pertussis, tetanus, and poliomyelitis in infants and children
- Booster immunization in pediatric populations
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
- Exploratory Clinical Study of MT-2301 (PHASE2)
- Phase 3 Study of BK1310 in Healthy Infants (PHASE3)
- Confirmatory Study of BK1310 in Healthy Infants (PHASE3)
- Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants (PHASE3)
- Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants (PHASE4)
- Influence of BCG on TDaP-IPV Vaccination (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DPT-IPV CI brief — competitive landscape report
- DPT-IPV updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI